Oral Carnitine in Heart Failure Patients
Oral L-Carnitine Supplementation in Cardiorenal Heart Failure Patients
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
20 participants
Nov 12, 2025
INTERVENTIONAL
Conditions
Summary
Heart failure is a condition in which the heart is unable to pump blood effectively, leading to symptoms like being more tired, shortness of breath, and swelling in the body. Carnitine is a naturally occurring substance in the body that plays a role in turning fat into energy. This study will determine whether oral L-Carnitine supplementation can improve symptoms, enhance heart function and possibly improve the quality of life in individuals with heart failure.
Eligibility
Inclusion Criteria5
- Clinical-pathological diagnosis of heart failure with some degree of cardiorenal syndrome
- Stage 1, 2, 3a, 3b, or 4 chronic kidney disease
- Age ≥ 18 years
- Able to speak and read English
- Willing and able to provide consent
Exclusion Criteria6
- Estimated GFR <15 mL/min/1.73m2 or Stage 5 chronic kidney disease
- Currently undergoing renal replacement therapy of any kind
- Pregnant, breastfeeding or intending pregnancy
- History of seizures of any type
- Known allergy to levocarnitine, magnesium stearate, microcrystalline cellulose or povidone
- Unable to provide consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral L-carnitine, 2970mg daily (950mg, to be taken 3 times a day) for 3 months.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07201714